BLCO Bausch & Lomb Corp
Ophthalmic Goods · NYSE · SEC CIK 1860742 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.9%
TTM net income YoY63.6%
TTM EPS YoY62.8%
Revenue 3-yr CAGR10.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin7.1%
Net margin-2.0%
FCF margin4.7%
EBITDA margin14.5%
Returns
ROE-1.7%
ROA-0.8%
ROIC (approx.)2.8%
Asset turnover0.39x
Leverage & solvency
Liabilities / assets53.4%
Debt / equity0.78x
Current ratio1.56x
Interest coverage1.00x
Cash quality & payout
Operating cash flow / net income-4.99x
Accruals ratio-4.8%
Payout ratio—
Capex / revenue5.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $5.10B | $4.79B | $4.15B | $3.77B | $3.77B |
| R&D expense | $371.00M | $343.00M | $324.00M | $307.00M | $271.00M |
| SG&A expense | $2.23B | $2.08B | $1.74B | $1.48B | $1.39B |
| Operating income | $113.00M | $162.00M | $130.00M | $207.00M | $329.00M |
| Interest expense | $421.00M | $399.00M | $283.00M | $146.00M | $0 |
| Pretax income | -$317.00M | -$234.00M | -$166.00M | $73.00M | $318.00M |
| Income tax | $35.00M | $71.00M | $82.00M | $58.00M | $125.00M |
| Net income | -$360.00M | -$317.00M | -$260.00M | $6.00M | $182.00M |
| EBITDA | $534.00M | $598.00M | $512.00M | $586.00M | $744.00M |
| EPS (basic) | -1.02 | -0.90 | -0.74 | 0.02 | 0.52 |
| EPS (diluted) | -1.02 | -0.90 | -0.74 | 0.02 | 0.52 |
| Weighted avg. shares (diluted) | 353.80M | 351.80M | 350.50M | 350.20M | 350.00M |
| Balance sheet | |||||
| Cash & equivalents | $383.00M | $316.00M | $334.00M | $380.00M | $177.00M |
| Receivables | $1.22B | $1.03B | $839.00M | $724.00M | $721.00M |
| Inventory | $976.00M | $1.04B | $1.03B | $628.00M | $572.00M |
| Current assets | $2.98B | $2.79B | $2.74B | $2.14B | $1.64B |
| PP&E, net | $1.76B | $1.49B | $1.39B | $1.30B | $1.23B |
| Goodwill | $4.76B | $4.52B | $4.58B | $4.51B | $4.59B |
| Intangibles | $3.28B | $3.49B | $3.59B | $2.06B | $2.26B |
| Total assets | $14.02B | $13.47B | $13.44B | $11.14B | $10.82B |
| Current liabilities | $1.92B | $1.74B | $1.58B | $1.30B | $1.10B |
| Short-term debt | $28.00M | $40.00M | $30.00M | $25.00M | $0 |
| Long-term debt | $5.02B | $4.74B | $4.53B | $2.41B | $0 |
| Total debt | $5.05B | $4.78B | $4.56B | $2.44B | $0 |
| Total liabilities | $7.50B | $6.92B | $6.52B | $4.04B | $1.42B |
| Shareholders' equity | $6.45B | $6.47B | $6.85B | $7.03B | $9.33B |
| Net debt | $4.67B | $4.47B | $4.23B | $2.06B | -$177.00M |
| Shares outstanding | 354.21M | 352.40M | 350.91M | 350.00M | 350.00M |
| Cash flow statement | |||||
| Operating cash flow | $283.00M | $232.00M | -$17.00M | $345.00M | $873.00M |
| Capital expenditure | $349.00M | $291.00M | $181.00M | $175.00M | $193.00M |
| Free cash flow | -$66.00M | -$59.00M | -$198.00M | $170.00M | $680.00M |
| Investing cash flow | -$455.00M | -$412.00M | -$2.11B | -$215.00M | -$214.00M |
| Financing cash flow | $225.00M | $178.00M | $2.08B | $81.00M | -$712.00M |
| Depreciation & amortization | $421.00M | $436.00M | $382.00M | $379.00M | $415.00M |
| Stock-based compensation | $149.00M | $92.00M | $74.00M | $62.00M | $62.00M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.